Optum Rx Weight Engage helps members achieve and sustain their weight loss goals through behavior modification support, such as diet and exercise planning
In addition to bodyweight loss through lifestyle interventions, pharmacotherapies targeting adipose tissue, the digestive system (gut-liver axis) and/or inflammation are warranted
Canadian research institutions actively participate in GLP-1 agonist research, including cardiovascular outcomes studies
The SURMOUNT-4 trial (Aronne 2023, JAMA) showed that adults who stopped tirzepatide after 36 weeks regained an average of 14.0% of body weight over the next 52 weeks, while those who continued tirzepatide lost an additional 5.5% a 19.4% between-group difference
Zero Waste Win: Unlike pills that lose over 98% in folks with issues like pernicious anemia, this IV ensures nothing goes unused
Also, of note fully 50% of the 1mg group dropped out of the trial and not because of side effects